Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients

Thrombosis and Haemostasis

Volumn 86, Issue 3, 2001, Pages 791-799

  Zareba, W ^a   Pancio, G ^a   Moss, A J ^a   Kalaria, V G ^a   Marder, V J ^a   Weiss, H J ^a   Miller Watelet, L F ^a   Sparks, C E ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Diabetes; Myocardial infarction; PAI 1; vWF

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 7; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPROTEIN; NITRATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGED; ANALYZER; ARTICLE; CARDIOVASCULAR PERFORMANCE; CONTROLLED STUDY; COVARIANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRESSLER SYNDROME; ENDOTHELIUM INJURY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; THROMBOGENESIS;

EID: 0034847059     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616133     Document Type: Article

References (53)

1. Acute myocardial infarction in the diabetic patient: Pathophysiology, clinical course and prognosis
2. Ten-year survival after acute myocardial infarction: Comparison of patients with and without diabetes
3. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction
4. Diabetes, other risk factors and 2-year cardiovascular mortality for men screened in the MRFIT trial
5. Coronary plaque disruption
6. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
7. Mechanisms of disease: Regulatory functions of the vascular endothelium
8. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart study
9. Population-based distributions of haemostatic variables
10. Von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death
11. Von Willebrand factor, endothelial cell damage and atherosclerosis
12. Predictive values of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: A 7-year follow-up
13. Plasminogen activator inhibitor in plasma: Risk for recurrent myocardial infarction
14. Fibrinogen and risk of cardiovascular disease. The Framingham study
15. Hemorheological changes following acute myocardial infarction
16. Changes in Lp(a) lipoprotein and other plasma proteins during acute myocardial infarction
17. Contribution of thrombogenic factors to the pathogenesis of atherosclerosis
18. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: A case-controlled study
19. Endothelial dysfunction in the acute myocardial infarction after reperfusion
20. Increased heparin-releasable platelet factor 4 and D-dimer in patients one month after the onset of acute myocardial infarction: Persistent activation of platelets and the coagulation/fibrinolytic system
21. Increased plasma concentration of crossed-linked fibrin polymers in acute myocardial infarction
22. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: The Scottish Heart Health Study
23. Diabetes, fibrinogen and risk of cardiovascular disease: The Framingham experience
24. Blood coagulation and fibrinogen in men after a myocardial infarction compared with a representative population sample
25. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
26. Caerphilly collaborative heart disease studies
27. Coagulation and fibrinolytic system impairment insulin-dependent diabetes mellitus
28. Plasminogen activator inhibitor (PAI-1) promoter polymorphism and coronary artery disease in NIDDM
29. The fibrinolytic system in diabetes mellitus
30. Albuminuria, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus
31. Increased plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
32. Relationships between insulin, triglyceride, body mass index, plasminogen activator inhibitor-1
33. Changes of fibrinolysis and factor VIII coagulant, antigen, and ristocetin co-factor in diabetes mellitus and atherosclerosis
34. Diabetes mellitus and hypertension: Emerging therapeutic perspectives
35. Thrombogenic factors and recurrent cardiac events
36. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens
37. Heterogenous abnormalities in multimeric structure, antigenic properties, and plasma/platelet content of FVII/vWF in classical (Type I) and three subtypes of variant (Type II) von Willebrands's disease
38. Clinical aspects of congenital factor VII deficiency
39. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
40. Measurement of plasminogen activator inhibitor-1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay
41. Measurement of crosslinked fibrin degradation products: An immunoassay using monoclonal antibodies
42. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparation ultracentrifuge
43. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study
44. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria
45. The cardiovascular risk factor plasminogen activator inhibitor type-I is related to insulin resistance
46. Plasminogen activator inhibitor (PAI-1) and non-insulin-dependent diabetes in PIMA Indians, South Asians, and Europeans
47. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor-1 in blood in normal human subjects
48. Fibrinogen plasma levels as a marker of thrombin activation in diabetes
49. Plasma fibrinogen in NIDDM: The Rotterdam Study
50. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin dependent diabetes mellitus
51. Lipoprotein physiology in nondiabetic and diabetic states: Relationship to atherosclerosis
52. Lipoprotein metabolism in diabetes mellitus
53. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus